CS173691A3 - Derivatives of /(1-arylpyrrolidin-2-yl)methyl/piperazine, process for their preparation and their use in therapy - Google Patents

Derivatives of /(1-arylpyrrolidin-2-yl)methyl/piperazine, process for their preparation and their use in therapy Download PDF

Info

Publication number: CS173691A3
Authority: CS; Czechoslovakia
Prior art keywords: formula; group; compounds; solvent; compound
Prior art date: 1990-06-07

Application number

CS911736A

Other languages

Czech (cs)

English (en)

Inventor

Pascal George

Jacques Menin

Jean-Pierre Merly

Dennis Bigg

Daniel Obitz

Michel Peynot

Corinne Veronique

Original Assignee

Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-07

Filing date

1991-06-06

Publication date

1992-02-19

1991-06-06 Application filed by Synthelabo filed Critical Synthelabo

1992-02-19 Publication of CS173691A3 publication Critical patent/CS173691A3/cs

Links

125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title claims abstract description 9
238000000034 method Methods 0.000 title claims description 7
238000002360 preparation method Methods 0.000 title claims description 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title description 8
238000002560 therapeutic procedure Methods 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 55
239000002253 acid Substances 0.000 claims abstract description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
150000003839 salts Chemical class 0.000 claims abstract description 6
125000005843 halogen group Chemical group 0.000 claims abstract description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 30
-1 trimethylaluminum amine Chemical class 0.000 claims description 19
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 11
239000002904 solvent Substances 0.000 claims description 9
238000006243 chemical reaction Methods 0.000 claims description 8
239000012442 inert solvent Substances 0.000 claims description 6
150000001408 amides Chemical class 0.000 claims description 5
239000012280 lithium aluminium hydride Substances 0.000 claims description 5
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 4
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
239000010949 copper Substances 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
239000000010 aprotic solvent Substances 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
125000001309 chloro group Chemical group Cl* 0.000 claims description 2
229910052802 copper Inorganic materials 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
150000004820 halides Chemical class 0.000 claims description 2
JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
101150047265 COR2 gene Proteins 0.000 abstract description 2
208000012902 Nervous system disease Diseases 0.000 abstract description 2
101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 abstract description 2
150000007513 acids Chemical class 0.000 abstract description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
208000025966 Neurological disease Diseases 0.000 abstract 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
239000000243 solution Substances 0.000 description 27
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
239000000203 mixture Substances 0.000 description 18
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
239000011541 reaction mixture Substances 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
239000003921 oil Substances 0.000 description 9
239000007787 solid Substances 0.000 description 9
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical class [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 7
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000002844 melting Methods 0.000 description 6
230000008018 melting Effects 0.000 description 6
239000012074 organic phase Substances 0.000 description 6
238000010992 reflux Methods 0.000 description 6
239000000872 buffer Substances 0.000 description 5
239000012265 solid product Substances 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
238000010171 animal model Methods 0.000 description 4
239000000460 chlorine Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 3
230000002253 anti-ischaemic effect Effects 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
230000027455 binding Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
230000002490 cerebral effect Effects 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
229910001629 magnesium chloride Inorganic materials 0.000 description 3
239000000047 product Substances 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
239000000725 suspension Substances 0.000 description 3
LKUAPSRIYZLAAO-UHFFFAOYSA-N 1-(2-phenylethyl)piperazine Chemical compound C1CNCCN1CCC1=CC=CC=C1 LKUAPSRIYZLAAO-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
208000010496 Heart Arrest Diseases 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
230000007059 acute toxicity Effects 0.000 description 2
231100000403 acute toxicity Toxicity 0.000 description 2
230000001773 anti-convulsant effect Effects 0.000 description 2
239000012300 argon atmosphere Substances 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
230000002920 convulsive effect Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000013256 coordination polymer Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
150000004678 hydrides Chemical class 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000000376 reactant Substances 0.000 description 2
239000013049 sediment Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
LNXYALHPFVINEA-UHFFFAOYSA-N (1-phenylpyrrolidin-2-yl)-piperazin-1-ylmethanone Chemical compound C1CNCCN1C(=O)C1CCCN1C1=CC=CC=C1 LNXYALHPFVINEA-UHFFFAOYSA-N 0.000 description 1
IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
206010008089 Cerebral artery occlusion Diseases 0.000 description 1
208000018152 Cerebral disease Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
101000582254 Homo sapiens Nuclear receptor corepressor 2 Proteins 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
208000026680 Metabolic Brain disease Diseases 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
206010038669 Respiratory arrest Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
206010043994 Tonic convulsion Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
208000037863 aminoacidopathy Diseases 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
238000009835 boiling Methods 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000006264 debenzylation reaction Methods 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000009297 electrocoagulation Methods 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
UBOKMOJCDSOTQY-UHFFFAOYSA-N ethyl 1-phenylpyrrolidine-2-carboxylate Chemical compound CCOC(=O)C1CCCN1C1=CC=CC=C1 UBOKMOJCDSOTQY-UHFFFAOYSA-N 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003447 ipsilateral effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
201000007309 middle cerebral artery infarction Diseases 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000003955 neuronal function Effects 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
210000001034 respiratory center Anatomy 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

CS911736A 1990-06-07 1991-06-06 Derivatives of /(1-arylpyrrolidin-2-yl)methyl/piperazine, process for their preparation and their use in therapy CS173691A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9007067A FR2663026B1 (fr)	1990-06-07	1990-06-07	Derives de [(1-arylpyrrolidin-2-yl) methyl] piperazine, leur preparation et leur application en therapeutique.

Publications (1)

Publication Number	Publication Date
CS173691A3 true CS173691A3 (en)	1992-02-19

Family

ID=9397358

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS911736A CS173691A3 (en)	1990-06-07	1991-06-06	Derivatives of /(1-arylpyrrolidin-2-yl)methyl/piperazine, process for their preparation and their use in therapy

Country Status (21)

Country	Link
US (1)	US5192763A (de)
EP (1)	EP0461012B1 (de)
JP (1)	JPH04235958A (de)
KR (1)	KR100188902B1 (de)
AT (1)	ATE104662T1 (de)
AU (1)	AU634391B2 (de)
CA (1)	CA2043981A1 (de)
CS (1)	CS173691A3 (de)
DE (1)	DE69101740T2 (de)
DK (1)	DK0461012T3 (de)
ES (1)	ES2054460T3 (de)
FI (1)	FI97055C (de)
FR (1)	FR2663026B1 (de)
HU (1)	HU209620B (de)
IE (1)	IE64688B1 (de)
IL (1)	IL98372A (de)
NO (1)	NO177931C (de)
NZ (1)	NZ238431A (de)
PL (1)	PL165187B1 (de)
PT (1)	PT97885B (de)
ZA (1)	ZA914339B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1245712B (it) *	1991-04-09	1994-10-14	Boehringer Mannheim Italia	Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
FR2684374B1 (fr) *	1991-12-02	1995-05-19	Synthelabo	Derives substitues de 1-[(1-arylpyrrolidin-2-yl)methyl]piperazine, leur preparation et leur application en therapeutique.
IT1255704B (it) *	1992-09-30	1995-11-10	Boehringer Mannheim Italia	Ammine eterocicliche utili nella terapia dell'asma e dell'infiammazione delle vie aeree

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3250771A (en) *	1962-12-17	1966-05-10	Geigy Chem Corp	5-monocarbocyclic aryl-n-lower alkyl-2-pyrrolidine carboxylic acid, esters, amides and derivatives thereof
GB1428493A (en) *	1973-05-02	1976-03-17	Science Union & Cie	Heterocyclic amides processes for their preparation and pharma ceutical compositions containing them
US5063242A (en) *	1989-04-21	1991-11-05	Warner-Lambert Company	7-((substituted)amino)-8-((substituted)carbonyl)-methylamino-1-oxaspiro[4,5]decanes as diuretics antiinflammatory, and cerebrovascular agents

1990
- 1990-06-07 FR FR9007067A patent/FR2663026B1/fr not_active Expired - Fee Related
1991
- 1991-06-03 AT AT9191401431T patent/ATE104662T1/de not_active IP Right Cessation
- 1991-06-03 DK DK91401431.1T patent/DK0461012T3/da active
- 1991-06-03 DE DE69101740T patent/DE69101740T2/de not_active Expired - Fee Related
- 1991-06-03 EP EP91401431A patent/EP0461012B1/de not_active Expired - Lifetime
- 1991-06-03 ES ES91401431T patent/ES2054460T3/es not_active Expired - Lifetime
- 1991-06-04 IL IL9837291A patent/IL98372A/en not_active IP Right Cessation
- 1991-06-06 ZA ZA914339A patent/ZA914339B/xx unknown
- 1991-06-06 CA CA002043981A patent/CA2043981A1/en not_active Abandoned
- 1991-06-06 PL PL91290572A patent/PL165187B1/pl unknown
- 1991-06-06 IE IE194191A patent/IE64688B1/en unknown
- 1991-06-06 JP JP3134761A patent/JPH04235958A/ja active Pending
- 1991-06-06 NO NO912168A patent/NO177931C/no not_active IP Right Cessation
- 1991-06-06 PT PT97885A patent/PT97885B/pt not_active IP Right Cessation
- 1991-06-06 FI FI912733A patent/FI97055C/fi active
- 1991-06-06 NZ NZ238431A patent/NZ238431A/xx unknown
- 1991-06-06 US US07/710,711 patent/US5192763A/en not_active Expired - Fee Related
- 1991-06-06 CS CS911736A patent/CS173691A3/cs unknown
- 1991-06-06 HU HU911895A patent/HU209620B/hu not_active IP Right Cessation
- 1991-06-06 AU AU78196/91A patent/AU634391B2/en not_active Ceased
- 1991-06-07 KR KR1019910009395A patent/KR100188902B1/ko not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU7819691A (en)	1991-12-12
HU209620B (en)	1994-09-28
ZA914339B (en)	1992-03-25
ATE104662T1 (de)	1994-05-15
PT97885A (pt)	1992-03-31
FR2663026A1 (fr)	1991-12-13
NO177931B (no)	1995-09-11
DE69101740T2 (de)	1994-10-20
HU911895D0 (en)	1991-12-30
IL98372A0 (en)	1992-07-15
KR100188902B1 (ko)	1999-06-01
IE911941A1 (en)	1991-12-18
NO912168L (no)	1991-12-09
NO177931C (no)	1995-12-20
US5192763A (en)	1993-03-09
DK0461012T3 (da)	1994-09-12
EP0461012B1 (de)	1994-04-20
HUT58070A (en)	1992-01-28
NZ238431A (en)	1992-09-25
EP0461012A1 (de)	1991-12-11
DE69101740D1 (de)	1994-05-26
PT97885B (pt)	1998-10-30
AU634391B2 (en)	1993-02-18
JPH04235958A (ja)	1992-08-25
ES2054460T3 (es)	1994-08-01
FI97055B (fi)	1996-06-28
IL98372A (en)	1996-01-31
CA2043981A1 (en)	1991-12-08
FI912733L (fi)	1991-12-08
PL165187B1 (pl)	1994-11-30
KR920000751A (ko)	1992-01-29
FR2663026B1 (fr)	1992-08-07
NO912168D0 (no)	1991-06-06
FI97055C (fi)	1996-10-10
FI912733A0 (fi)	1991-06-06
IE64688B1 (en)	1995-08-23
PL290572A1 (en)	1992-02-10

Publication	Publication Date	Title
DE60315615T2 (de)	2008-10-02	Tricyclische verbindungen basierend auf thiophen und arzneimittel, die diese umfassen
US7335670B2 (en)	2008-02-26	Derivatives of N-[heteroaryl(piperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics
DE69613705T2 (de)	2002-05-16	Piperinderivate als neurokininantagoniste
JP7098663B2 (ja)	2022-07-11	ピペリジノンホルミルペプチド２受容体アゴニスト
PL185029B1 (pl)	2003-02-28	Nowa 1-(1,2-dwupodstawiona-piperydynylo)-4-podstawiona pochodna piperazyny, kompozycja farmaceutyczna, sposób wytwarzania kompozycji farmaceutycznej i sposób wytwarzania 1-(1,2-dwupodstawionej-piperydynylo)-4-podstawionej pochodnej piperazyny
US5210086A (en)	1993-05-11	2-aminopyrimidine-4-carboxamide derivatives, their preparation and their use in therapy
EP0275696B1 (de)	1992-04-01	Piperidinderivate
US7928099B2 (en)	2011-04-19	Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists
AU680626B2 (en)	1997-08-07	1,4-disubstituted piperazines useful in the therapy of the asthma and of the inflammation of the respiratory tract
DE69414855T2 (de)	1999-07-08	N-(piperidinyl-1-alkyl)-substituierte cyclohexancarbonsäureamide als 5ht1a rezeptor antagonisten
CA2354213C (en)	2010-04-27	N-triazolylmethyl-piperazine compounds with neurokinin-receptor antagonist activity
AU705683B2 (en)	1999-05-27	Piperazino derivatives as neurokinin antagonists
EA008148B1 (ru)	2007-04-27	Новые соединения, их применение и получение
US5166156A (en)	1992-11-24	Naphthyl piperazines useful as 5-HT1A receptor ligands
CS173691A3 (en)	1992-02-19	Derivatives of /(1-arylpyrrolidin-2-yl)methyl/piperazine, process for their preparation and their use in therapy
DE602004004550T2 (de)	2007-11-22	Substituierte heterocyclische verbindungen und anwendungsverfahren
KR101771794B1 (ko)	2017-08-25	트리아졸로-아릴아크릴로나이트라일 유도체 및 이의 용도
US5066651A (en)	1991-11-19	Pyrrolidone compounds for treating cerebral disorders
IE900027L (en)	1990-07-10	New bis(aryl)alkene derivatives, processes for preparing¹them and pharmaceutical compositions containing them
US5068231A (en)	1991-11-26	Method of treating muscular tension, muscle spasticity and anxiety with 3-aryloxy and 3-arylthioazetidinecarboxamides
US5166157A (en)	1992-11-24	Naphthyl piperazines useful as 5-HT1A receptor ligands
US5183902A (en)	1993-02-02	Method of treating muscular tension, muscle spasticity and anxiety with 3-aryloxy and 3-arylthioazetidinecarboxamides
US5162321A (en)	1992-11-10	1-naphthyl piperazines useful as 5-HT1A receptor ligands
US5151418A (en)	1992-09-29	Method of treating muscular tension, muscle spasticity and anxiety with 3-aryloxy and 3-arylthioazetidinecarboxamides
US5162324A (en)	1992-11-10	Naphyl piperazines useful as 5-HT1A receptor ligands